In 97 unselected volunteers and two additional homozygous carriers of CYP2C9*3, we investigated the oral clearance of torsemide in relation to 37 polymorphisms at the CYP2C gene locus. Torsemide total oral clearance was linearly associated with the number of CYP2C9*3 alleles (geometric mean: 59, 40 and 20 ml/min in carriers of no, one and two alleles) and so were the methyl-and ring-hydroxylation but not the carboxylation clearance. Haplotypes including the CYP2C9*3 allele were similarly associated with the clearances but no other variant and no haplotype not including the CYP2C9*3 variant. The extended haplotype length (EHL) of the CYP2C9 haplotypes was positively associated with higher activity of the gene product. Torsemide total oral clearance was predictable with r 2 ¼ 82.1% using plasma concentrations at 0.5, 1, 2 and 24 h. In conclusion, torsemide's biotransformation strongly depended on the CYP2C9*3 variant but no other. Higher clearance CYP2C9 haplotypes appear to be evolutionarily selected.
Introduction
The four drug metabolizing enzymes CYP2C8, CYP2C9, CYP2C18 and CYP2C19 contribute to the biotransformation of about 30% of all drugs. The coding genes are located at a common CYP2C gene locus. Considering the large number of clinically used substrates, including all vitamin K antagonistic oral anticoagulants, almost all sulfonylurea oral antidiabetic drugs and most nonsteroidal antiinflammatory agents, CYP2C9 may be most important among the CYP2C enzymes.
1-4 CYP2C8 plays a major role in the metabolism of cerivastatin, chloroquine, paclitaxel, repaglinide, rosiglitazone, verapamil and zopiclone. 5, 6 CYP2C19 predominantly metabolizes almost all proton pump inhibitors, several antidepressants, the protease inhibitor nelfinavir and the imidazole antimycotic voriconazol. 3, 7, 8 The role of CYP2C18 is less clear; it is expressed poorly in the liver; CYP2C18 is expressed significantly in the skin and tissue-specific bioactivation of phenytoin by CYP2C18 has been associated with phenytoin's dermal drug toxicity. 9 Genetic variation in the four CYP2C genes and its clinical consequences have been widely studied.
2,3,5,10-13 CYP2C9*3, an lle359Leu substitution affects the maximum reaction rate of almost all currently known CYP2C9 substrates, CYP2C9*2, Arg144Cys, differentially affects the metabolism of some drugs more than of others. 2 Except for CYP2C8*2 and *3, CYP2C9*2 and *3 and CYP2C19*2 functional amino acid substitutions in CYP2C genes are rare in Caucasian populations (compare www.imm.ki.se/CYPalleles/). For CYP2C9 substrates, more than 80% of the interindividual variation in pharmacokinetics remain unexplained by the known polymorphisms. Thus, the search has focused on regulatory regions and indeed some evidence for functional polymorphisms in the CYP2C9 regulatory regions has been reported. 14, 15 The extended haplotype homozygosity (EHH) method is a new screening method to detect recent positive selection in the human genome from haplotype structure. 16 It relies on the breakdown of haplotypes including a new mutation over time by recombination processes. Positive selection is assumed the longer a haplotype at a locus of interest extends in relation to its frequency and other haplotypes. The EHH method has the potential to differentiate between variants, which were evolutionarily selected due to their functional benefits for the organism from those variants, which have merely been selected due to linkage to a primarily selected variant. 17, 18 Torsemide is a loop diuretic drug quite specifically metabolized by CYP2C9. 19, 20 Methyl-and phenyl-hydroxylation form metabolites termed M1 and M3. M1 is further oxidized to the carboxylated metabolite M5. Torsemide clearance was greatly reduced in carriers of the CYP2C9*3 variant but not in carriers of the CYP2C9*2 variant in accordance with in vitro findings. 2, 19, 21, 22 Torsemide may therefore be a valuable CYP2C9 probe drug with specific properties compared to the other commonly used substrates tolbutamide, 23 warfarin [24] [25] [26] or losartan. 27 Phenotyping unselected samples has lead to the identification of functionally relevant genetic polymorphisms. 28, 29 Here, we applied this approach to the CYP2C locus using torsemide as the phenotyping drug. After extensive search for amino acid polymorphisms has been unsuccessful, we focused to detect polymorphisms affecting gene regulation. We therefore calculated haplotypes and performed haplotype-phenotype association.
Results

Study population
The 97 unselected healthy male Caucasian volunteers, who participated in the clinical study had a mean (range) age of 28 years (19-50 years). The mean body weight and height were 78 kg (57-93 kg) and 182 cm (170-198 cm), and the mean body surface was 2.0 m 2 (range 1.7-2.3 m 2 ).
Genetic variation at the CYP2C locus
In total, 37 potential polymorphisms were investigated ( Figure 1 ). Four of them turned out to be monomorphic and are not discussed further. The allele frequencies of the minor alleles were above 0.05 except for rs1409654 in CYP2C18 and rs1058930 in CYP2C8 (Table 1 ). The polymorphisms formed three linkage disequilibrium (LD) blocks. One LD block included CYP2C18 and CYP2C19 and each one LD block included CYP2C9 or CYP2C8 (Figure 2 ). There are controversies concerning the LD block definition at the CYP2C locus. 30, 31 With our data set, all applied algorithms for LD block definition came essentially to the same grouping with the only relevant difference concerning whether or not to include some of the 5 0 polymorphisms of the CYP2C9 locus into the CYP2C18-CYP2C19 block. Inclusion of the most 5 0 CYP2C9 polymorphism subdivided the most frequent haplotype at the CYP2C18-CYP2C19 including LD block into two subhaplotypes. Inclusion of further polymorphisms merely resulted in lower frequencies Figure 1 Gene structure and location of the studied polymorphisms at the cytochrome P450 2C (CYP2C) locus. This figure depicts the location of the CYP2C locus on chromosome 10, the proportional size and location of the four genes including direction of transcription (arrows), gene borders and intron-exon structure and the chromosomal position and rs number of the investigated polymorphisms as given by the NCBI databases Map Viewer, Gene and SNP (NCBI build 35.1). In some cases, no rs number was available. Then the hCV-number referring to the Celera SNP database is given or the polymorphism is termed goe1 or goe1plus2. Putative polymorphisms that turned out monomorphic are given in grey letters.
of the major haplotypes and the prediction of additional infrequent haplotypes.
Five, five and six frequent haplotypes (allele frequency 42%) were observed at the CYP2C18-CYP2C19, CYP2C9 and CYP2C8 LD block, respectively (Table 2) . Four, four and five tagging SNPs identified these frequent haplotypes at the respective LD block ( CYP2C18-CYP2C19 and the CYP2C8 haplotypes, respectively. Haplotype calculation including all polymorphisms revealed individual coupling among the haplotyes at the three LD blocks described above ( Figure 3 ). Concerning polymorphisms known to be functional, H3, which includes the CYP2C19*2 variant, is tightly coupled with the CYP2C9 haplotype H8 and the CYP2C8 haplotype H16 that includes the CYP2C8*4 variant. The CYP2C9 haplotypes H9 and H10, defined by CYP2C9*2 and CYP2C9*3, are particularly tightly coupled to neighbouring haplotypes at the CYP2C18-CYP2C19 locus. H9 is also coupled to the CYP2C8 haplotype H14, which includes the CYP2C8*3 variant. Two subhaplotypes of CYP2C9 haplotypes were observed. A subgroup of H8 was coupled to H5 and H12 (H5-H8-H12) and a subgroup of H1 and H6 is tightly coupled to the CYP2C8 haplotype H15, a combination that has a frequency of 7.7% (H1-H15 and H6-H15).
Torsemide metabolic phenotype
The total oral torsemide clearance, the extrarenal clearance and both hydroxylation clearances were log-normally distributed, the secondary carboxylation clearance was normally distributed ( Figure 4 ). The geometric (logarithmic) mean of the total oral torsemide clearance was 54.4 ml/min in the unselected study population (52.5-56.4 ml/min 7s.e.m., range 25.8-128.2 ml/min; Figure 4 ). The geometric mean value of the extrarenal torsemide clearance was 38.3 ml/min (36.8-39.9, range 16.1-97.5 ml/min). The geometric mean methyl hydroxylation clearance was 26.4 ml/ min (24.8-28.0, range 1.7-120.8 ml/min) and was an order of magnitude lower for the ring hydroxylation clearance with 1.4 ml/min (1.3-1.5, range 0.4-6.0 ml/min). Taken together, renal, methyl and ring hydroxylation clearances left about 15% of the total oral torsemide clearance unexplained. The arithmetic mean of the normally distributed carboxylation clearance was 156 ml/min (162-150, range 31-315 ml/min).
Genoptype-phenotype association
Most of the 17 heterozygous carriers of a CYP2C9*3 allele had total and hydroxylation clearances below the mean value; the carboxylation clearance was apparently independent from the CYP2C9*3 polymorphism (Figure 4 ). The geometric mean values of the total oral torsemide clearance was 58.6 ml/min (56.5-60.87s.e.m., range 28.7-128.2 ml/ min) in the carriers of no CYP2C9*3 allele. In the heterozygous group, mean oral torsemide clearance was 40.3 ml/ min (37.9-42.8, range 28.0-62.7 ml/min) and 19.9 ml/min (19.4 and 20.4 ml/min) in the two CYP2C9*3 homozygotes Figure 2 The linkage disequilibrium (LD) among the studied polymorphisms. This figure depicts the linkage between the polymorphisms and the resulting LD blocks at the CYP2C locus. Grey shaded boxes denote the attribution of the polymorphisms to the genes encoding the cyptochrome P450 enzymes CYP2C18, CYP2C19, CYP2C9 and CYP2C8. LD block size is given as horizontal bars as calculated by the software package Haploview, according to the '4 gamete rule', the 'solid spine of LD' and the 'confidence interval' method with the respective predefined settings. The LD blocks drawn below represent the LD blocks that were primarily used for the haplotype-phenotype association defined relying on the 'n þ 1' method of Zeggini et al. 43 The polymorphisms are identified as given in Table 1 and Figure 1 . Dark red boxes without a value denote a D 0 -value of 1.00; light blue boxes without a value denote a not determinable value. Numbers denote the 100-fold of the respective D 0 -values. The higher the value, the darker the fill colour of the boxes and the higher the LD.
CYP2C genetic variation and torsemide metabolism SV Vormfelde et al ( Figure 5 ). Thus, there was a linear relationship between the number of CYP2C9*3 alleles and the torsemide clearance.
The methyl and the ring hydroxylation clearances also depended linearly on the number of CYP2C9*3 alleles ( Figure 5 ). The major part of the secondary carboxylation clearance was independent of the CYP2C9*3 polymorphism or any other of the investigated polymorphisms or haplotypes ( Figure 5 ).
Total oral torsemide clearance was 20.778.8 ml/min in carriers of two CYP2C9*3 alleles compared to 61.972.2 ml/ min in carriers of no CYP2C9*3 allele in linear regression analysis (r 2 ¼ 18.4%, Po0.0001; Table 1 ). Correspondingly, the methyl hydroxylation clearance was 4.577.4 ml/min compared to 33.971.8 ml/min (r 2 ¼ 14.6%, P ¼ 0.0001) and ring hydroxylation clearance was 0.370.4 ml/min compared to 1.770.1 ml/min (r 2 ¼ 13.3%, P ¼ 0.0003). The association with the carboxylation clearance and the residual clearance was not significant (P ¼ 0.34 and 0.96). Neither the CYP2C9*2 nor any other polymorphism except the CYP2C9*3 allele was associated with any of the clearances even without correction for multiple testing (Table 1) .
Haplotype-phenotype association
The group of carriers of the haplotype H10 was identical with the group of CYP2C9*3 allele carriers resulting in identical association with the phenotype (Table 2) . None of the other haplotypes of CYP2C9 or of the CYP2C18-CYP2C19 or the CYP2C8 locus was associated with any of the phenotypes (Table 2 ). Haplotypes were also calculated using a number of further LD block definitions. These include those implied by Haploview (Figure 2 , upper part), an LD block over the whole CYP2C18-CYP2C19-CYP2C9 locus and an LD block including all frequent polymorphisms of the four CYP2C genes. In no case any frequent haplotype that did not include the CYP2C9*3 variant was associated with any phenotype even without correction for multiple testing.
In silico analyses concerning haplotype breakdown at the CYP2C locus were performed with polymorphisms analysed in 120 Caucasian chromosomes in the HapMap project www.hapmap.org. 32 The LD block including CYP2C9 identified by the software program Sweep spanned 16 polymorphisms and revealed eight haplotypes. Although only three of the polymorphisms were identical to those analysed in our sample, this data set revealed the haplotypes H7 to H10 having comparable frequencies (23, 17, 15 and 6%) as with our polymorphism set. The remaining four haplotypes amount to 40% and were subhaplotypes of H6. One of these four subhaplotypes was defined by the variant allele of rs2475377, had an allele frequency of 6.6% and due to its discrete linkage with variant alleles in the region of rs7912549 most likely resembled H6-H15 (Figure 3) . The remaining three subhaplotypes were defined as a group by the variant allele of rs2253635, and subdivided into H6-1 with no further variant (15.8% haplotype frequency) H6-2 with the variant allele of rs2475376 (10.8%) and H6-3 with the variant allele of rs9332197 (6.7%). The four subhaplotypes were tightly coupled with different variants outside CYP2C9 suggesting that they are related but discrete haplotypes. Figure 3 Coupling of haplotypes at the CYP2C locus. This figure depicts the coupling among the frequent haplotyes (those above 2% total frequency) at the gene loci CYP2C18-CYP2C19 and CYP2C8 in relation to the five frequent haplotypes at the CYP2C9 locus. The box height roughly resembles the haplotype frequency. CYP2C18-CYP2C19 and CYP2C8 haplotypes are given and named when occurring with above one percentage point frequency in the respective group defined by a CYP2C9 haplotype. Numbering of the haplotypes H1 through H16 is as in Table 2 . *2, *3 and *4 in brackets denote the variant alleles CYP2C19*2, CYP2C9*2 and *3 and CYP2C8*3 and *4. Coloured and dark grey fields resemble single nameable haplotypes; light grey fields denote a number of haplotypes with less than one per cent point frequency. H1-H15, H6-H15 and H5-H8-H12 denote subgroups of H1, H6 and H8 identical to the main group of H1, H6 and H8 but tightly coupled to a specific haplotype (H15, H5 and H12) at another LD block. Haplotypes including named polymorphisms and H6-H15 are coloured correspondingly to Figure 6 . Numbers to the left denote the corresponding CYP2C9 haplotype numbering of Veenstra et al. CYP2C genetic variation and torsemide metabolism
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The extended haplotype length (EHL) of the CYP2C9 haplotypes was remarkably long. The median EHL of the CYP2C9 haplotypes was 450 kb compared to 105 and 47 kb at the two other LD blocks near the CYP2C locus, which also spanned 16 polymorphisms. H6-H15 and H6-1 turned out the haplotypes with the greatest EHL, H6-2, H6-3, H8 and H9 intermediate and H7 and H10 had the shortest EHL ( Figure 6 ). Also the variants themselves that define the CYP2C9 haplotypes were associated with relatively long range EHH. The variant defining H10 (CYP2C9*3) had an EHL of approximately 300 kb and those defining H8 and H9 (CYP2C9*2) both had an EHL of approximately 400 kb. The H6-2 and H7 defining variants were associated with an EHL of 500 kb and the variants defining H6-3 and H6-15 with 700 and 900 kb EHL (H6-1 was not definable by a single variant in that data set). These EHLs compare to a median EHL of about 160 kb in those of the 717 variants with 0-0.25 allele frequency. Unfortunately, EHL could not be calculated in our Göttingen population because the extension of the CYP2C9 haplotypes exceeded the range of the analysed polymorphisms. This at least did not contradict the findings in the HapMap data set.
Nongenetic predictors of the torsemide metabolic phenotype Age, height, weight, body mass index (BMI), body surface and serum albumin concentration were not correlated with total torsemide clearance or any of the partial metabolite formation clearances even without adjustment for multiple testing.
CYP2C9 phenotype prediction with reduced sampling Best phenotype prediction was achieved calculating total oral torsemide clearance with area under the curve (AUC) estimates using a reduced number of plasma samples including those shown in Figure 7a . Of total oral torsemide clearance, 82.1% prediction was achieved calculating torsemide AUC from only four plasma samples at 0.5, 1, 2 and 24 h after torsemide intake (r 2 ¼ 82.1%, median prediction error of 7.8%, linear model forced through origin, Figure  7b ). Reduced sampling clearance underestimated the clearance compared to nonparametric analysis by 10.7%. Breakdown of CYP2C9 haplotypes with distance. This figure depicts the decline of the EHH with distance in four of the eight CYP2C9 haplotypes in the 120 Caucasian HapMap chromosomes (www.hapmap. org). The depicted haplotypes are H6-1, H6-H15, H9 (defined by the CYP2C9*2 allele) and H10 (defined by the CYP2C9*3 allele, numbering according to Table 2 ). In the gene track at the top, the open boxes proportionally resemble the size of genes at the locus, the genes CYP2C18, CYP2C19, CYP2C9 and CYP2C8 are named above the gene track. The vertical bars below the boxes resemble each one genotyped polymorphism, the bold ones resemble those 16 in the CYP2C9 including linkage disequilibrium (LD) block. The horizontal bars below denote the size and the position of the LD blocks automatically defined by Sweep.
Reduced sampling clearance was associated with the number of CYP2C9*3/H10 alleles with P ¼ 0.0002.
Restricting to three plasma samples clearance calculation from 1, 2 and 24 h samples reached acceptable r 2 ¼ 79.6%. Omitting the 24 h sample resulted in r 2 -values of maximally 55.3% (model 10 in Figure 7 ). Restricting to two plasma concentrations, the only prediction value above r 2 ¼ 50% was observed using the 2 and the 24 h concentration (model 13 in Figure 7 ). Single torsemide plasma concentrations and derivatives thereof were even less associated with the total oral torsemide clearance, irrespective of the association model employed. As a maximum, the plasma concentration at t ¼ 24 h p.a. predicted r 2 ¼ 24.4% of the total oral torsemide clearance (linear model).
To circumvent blood sampling, phenotype prediction from urine may be preferred. The relation A e M3 /A e torsemide and A e torsemide itself in the 10-24 h interval turned out the best predictors of the total oral torsemide clearance (r 2 ¼ 22.8 and 19.8% in linear models and below 35 % in all other models).
Discussion
In an earlier study in 36 selected subjects selected for CYP2C9*2 and *3 alleles, we demonstrated that torsemide's in vivo biotransformation depended on the CYP2C9*3 polymorphism but not on the CYP2C9*2 polymorphism. 21 As over 80% of interindividual variation in the metabolic clearance of torsemide remained unexplained, we investigate a larger population with an extended set of analysed polymorphisms. The CYP2C9*2 and the CYP2C9*3 allele each defined exactly one CYP2C9 haplotype. The dominant parts of the total oral torsemide clearance and the hydroxylation clearances are linearly associated with the number of alleles of the haplotype defined by CYP2C9*3 but not with CYP2C9*2 or any other of the 33 studied polymorphism. As the LD block definition at the CYP2C locus has recently been a matter of discussion, 30, 31 we evaluated haplotype-phenotype associations with haplotypes from a number of LD block definitions. This repetitively revealed the association with haplotypes including the CYP2C9*3 allele but not others. The secondary carboxylation clearance was independent from any variation in CYP2C9, including CYP2C9*3. None of the tested potential non-genetic predictors including body weight and body surface had a significant impact on the phenotype.
The linear form of the relationship between the number of CYP2C9*3 alleles and the torsemide clearance correspond to a codominant mode of inheritance (linear gene-dose effect) where the expression of the two alleles is (1) independent from each other and (2) not regulated via feedback substrate or product inhibition. In the present study, 1.1 ml/min or 13% of the methyl hydroxylation clearance and 0.3 ml/min or 20% of the ring hydroxylation clearance were not attributed to the CYP2C9*3 polymorphism (compare Figure  5 ) marking the upper limit of a contribution of enzymes other than CYP2C9 to the formation of these metabolites.
The CYP2C9*2 polymorphism is thought to alter the interaction of the CYP2C9 enzyme with the NADPH:cytochrome P450 oxidoreductase. 2, 33 In vitro, torsemide's metabolism was not affected by the CYP2C9*2 polymorphism supposedly as torsemide induces an anodic shift of CYP2C9 in favour of catalytic activity. 2, 19, 34 Clinical effects of the CYP2C9*2 variant, however, may also be due to linkage with other polymorphism alike CYP2C8*3 35 (Figure 3 ) or differential contributions of other CYP2C enzymes. In our study, none of the haplotypes at the CYP2C locus including the CYP2C9*2 variant was associated with torsemide's metabolic phenotype ( Table 2 ).
An extensive resequencing project covering 60 kb at the CYP2C9 locus revealed at least five distinct haplotype groups in 192 European American warfarin patients. 13 The five haplotypes in our population corresponded well to these five haplotype groups despite using different polymorphisms. The haplotypes H9 and H10, including CYP2C9*2 and CYP2C9*3, have been termed groups 2 and 3 by Veenstra et al. (Figure 3 ). H6, H7 and H8 compare to Veenstra's groups 1A, 1B and 1C. Extending over CYP2C9, we observed strong linkage of the CYP2C9 haplotypes with the haplotypes at the CYP2C18-CYP2C19 and the CYP2C8 locus (Figure 3) . Knowledge of such LD may be crucial to the interpretation of genotype-phenotype associations in that apparent association may in fact be due to association with a haplotype at a neighbouring gene.
The great length of the CYP2C9 haplotypes as a group observed in the 120 Caucasian HapMap chromosomes (and not contradicted by the findings in our subjects) implies recent positive selection of the now present CYP2C9 haplotypes. Among them, the EHL is positively associated with the clearance function of the resulting enzyme. This association might indicate positive selection for high clearing CYP2C9 alleles. As CYP2C9 metabolizes organic anions, it is striking that in a search for signals of evolutionary selection in 168 genes related to immune function the haplotype with the most outstanding haplotype length in Caucasians was the most frequent allele of the multispecific organic anion transporter gene ABCC1. 17 Well-established in vivo phenotyping probes for CYP2C9 activity are warfarin and tolbutamide. 4, 26, [36] [37] [38] Tolbutamide will probably not be available as a registered drug in the next years in many countries and warfarin requires more sophisticated enantiospecific analysis to be optimal. 39 Thus, one may think about alternative CYP2C9 phenotyping methods. Torsemide as a probe would be specific for CYP2C9 and pharmacogenetically only dependent on the CYP2C9*3 variant. Such selectivity may be helpful to study effects of CYP2C9 induction or inhibition including or not the effect of the CYP2C9*3 variant but without interference by the CYP2C9*2 variant. For the ease of study performance or a potential clinical application one may want to circumvent 24 h serum profiles or 24 h urine sampling as has recently, for example, been suggested for CYP3A4 phenotyping. 40 Prediction values of 82.2 and 79.8% using four or three plasma concentrations, respectively, are comparable to single point values well above r 2 ¼ 80% with CYP3A4 probes 40 and were sufficient to detect the association with the CYP2C9*3 genotype. However, no single point measure or measure from urine sampling reached any acceptable prediction value. Such weak predictability of the clearance from single point measures might indicate high variation in the volume of distribution or in the absorption time course.
In conclusion, torsemide is a CYP2C9 substrate with a hepatic clearance dependent on the CYP2C9*3 but not the CYP2C9*2 variant. We could not elucidate the basis for the about 80% variation in CYP2C9 activity unexplained by the CYP2C9*3 variant. Further studies like formal twin studies are required to reveal how much of the 80% unexplained inter-individual variability is really genetic. If truly genetic, this variation may be caused by trans-acting factors localized far away from the CYP2C locus or on other chromosomes. Sufficient prediction of total oral torsemide clearance may be achieved with only three to four plasma samples. Finally, we suggest an evolutionary preference for higher functional CYP2C9 alleles.
Materials and methods
Clinical study
An unselected population of 108 healthy healthy, nonsmoking, male volunteers aged between 19 and 50 years was screened. Ninety-seven of them plus two homozygous carriers of the CYP2C9*3 allele (total of 99 subjects) completed an open-label single-dose pharmacokinetic study. All subjects were white. All volunteers were healthy as confirmed by physical examination and routine laboratory analyses. The study was approved by the Ethics Committee of the Georg August University, Göttingen, Germany, and was carried out in accordance with the principles of the Declaration of Helsinki. All subjects provided written informed consent before inclusion in the study and after full explanation of all study procedures. A subpopulation of the study population presented here formed the population published earlier. 21 After an overnight fast, 10 mg torsemide (Unat; Roche Diagnostics GmbH, Mannheim, Germany) was administered orally after the subjects had emptied their bladder. Volunteers fasted until 4 h after drug administration. Blood samples were taken immediately before and at 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 h after dosage. Urine was collected in the respective intervals, weighed and a sample stored together with the plasma samples at À201C.
Genotyping
Genotyping was performed in the 108 screened subjects plus the two CYP2C9*3 homozygotes (total of 110 subjects). The location of the studied polymorphisms in the CYP2C gene locus is illustrated in Figure 1 . PCR primers and condition details are given in Table 3 . PCRs were carried out in a reaction volume of 15 ml with 6 ng genomic DNA, 10 mM dNTP, 10 mM of each forward and reverse oligonucleotide PCR primers, Taq polymerase (5 U/ml), 1.5 mM MgCl 2 (25 mM) . Genotyping was performed by Pyroseqencing on the PSQ HS96A System using standard protocols defined by the supplier and proprietary pyrosequencing software (Biotage AB, Uppsala, Sweden). Controls were included to exclude mix-ups and other errors during genotyping: DNAfree reaction mix and dedicated DNA. All polymorphisms were in Hardy-Weinberg equilibrium.
LD block definition and EHH test LD blocks were identified using the software Haploview, version 3.2. 41 The linkage plot relied on the D 0 value of Lewontin. 42 LD block definition is a critical matter of current evaluation and ongoing discussion. [43] [44] [45] Recently, the LD block definition at the CYP2C locus has been discussed controversially. 30, 31 The three nearly gene-wise LD blocks mainly used in this study were defined relying on the 'n þ 1' method of Zeggini et al. 43 The individual haplotypes were calculated using the software program Phase, version 2.1.1. 46, 47 Ten runs were performed starting from the seed values 2, 1536, 2936, 3122, 4957, 5283, 6757, 7992, 8633 and 9045. The haplotype pair most often assigned to the individuals was used for the genotypephenotype association.
The EHH and the EHL were explored using the software program Sweep, version 1.0, freely available from http:// www.broad.mit.edu/mpg/sweep/. Standard settings were used throughout. The EHH of single polymorphisms was explored defining LD blocks consisting solely of the very polymorphism. The EHL is the range demarked by 50% EHH breakdown to both sides of a given haplotype. 48 With our population we obtained the hint on relatively long EHL. However, the apparent extension of the haplotypes beyond the CYP2C locus prevented meaningful description of the haplotype breakdown, namely calculation of EHL, in our population. In addition, maximal density of genotyped polymorphism is mandatory for complete haplotype subdivision as incomplete haplotype subdivision results in falsely fast apparent breakdown of the incompletely subdivided haplotype. 48 We therefore used the publicly available phased data of 717 polymorphisms spanning a 2.4 Mb region from 95.2 to 97.6 Mb on chromosome 10 for the 120 Caucasian (CEU) chromosomes of the HapMap project from www.hapmap.org (release no. 19).
Drug concentration and pharmacokinetic analysis
The methods to measure torsemide, its methyl hydroxylated metabolite M1, M5, which is the corresponding 3-carboxylated metabolite, and the phenolic metabolite M3 in plasma and urine samples have been published earlier. 21, 49 The limit of quantification was 10 ng/ml for all analytes from plasma samples and 1 ng/ml for all analytes from urine samples. Pharmacokinetic analysis was performed with the nonparametric analysis module of the WinNonlin software, version 2.1. Torsemide total oral clearance was calculated as dose/ AUC with extrapolation to infinity (AUC torsemide 0-N ). The renal torsemide clearance was calculated as A e torsemide 0-N / AUC torsemide 0-N , where A e torsemide 0-N is the amount of torsemide excreted unchanged in the urine extrapolated to infinity; the extrarenal torsemide clearance was then total oral minus renal torsemide clearance. Three metabolite AUCs were calculated by the linear trapezoidal rule as individual duration of the interval times the mean of the respective plasma concentrations at the beginning and the end of the interval. In most instances, in the interval including the concentration at 24 h, the AUC was calculated by the log-linear trapezoidal rule as ten to the power of the mean of the logarithms to the basis 10 of the concentrations at the beginning and at the end of the interval. In the model specified in the results section, a value of 10 mg/l was added to the 24 h concentration resulting in a calculation of the clearance as 10mg P interval AUCs up to time tþ10 0:5Ãðlog 10 ðconcentration at tÞþlog 10 ðconcentration at 24hþ10 mg=lÞÞ
Further tested potential predictors included inverse serum concentrations and the quotients of M1, M5 or M1 þ M5 per torsemide concentrations. We also tested the A e of torsemide, the three metabolites and the summed metabolites M1 þ M5 and M1 þ M3 þ M5 as well as the inverses of these each in the respective interval and summed up from the time after intake to the end of the very interval. Finally, we explored the quotients of the A e of the metabolites and their sums per A e torsemide . We explored a number of models including linear, potential and exponential relationship. Besides the determination coefficient we calculated the mean prediction error (bias) that has been discussed to provide additional information. 50 
Data analysis
Association with the torsemide clearances was performed by two-sided linear regression analysis using the software package SPSS, version 12.0.0, Po0.05 was considered significant. Linear regression analysis was performed with the number of CYP2C9*3 as independent predictor. Any further linear regression analysis was performed controlled for the effect of the CYP2C9*3 allele, if not stated otherwise. The Shapiro-Wilk test was used to test for normal distribution of the data.
